Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 plus Toripalimab in PD-(L)1 Refractory classic Hodgkin Lymphoma
NCT06170489Phase 3Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tifcemalimab in classic Hodgkin lymphoma (cHL), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Dec 2023; status: recruiting.
02
Drugs
tifcemalimab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06170489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170489.